Acute myeloid leukemia
Acute Myeloid Leukemia | New England Journal of Medicine Skip to main content The New
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES Cardiology …
An update on VEXAS syndrome
A Al-Hakim, S Savic - Expert Review of Clinical Immunology, 2023 - Taylor & Francis
Introduction VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome
is a recently described, late-onset, acquired autoinflammatory disorder caused by mutations …
is a recently described, late-onset, acquired autoinflammatory disorder caused by mutations …
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel
T De Witte, D Bowen, M Robin… - Blood, The Journal …, 2017 - ashpublications.org
An international expert panel, active within the European Society for Blood and Marrow
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …
Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group …
Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced …
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
PL Greenberg, RM Stone, A Al-Kali, SK Barta… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
Acute myeloid leukemia: 2014 Update on risk‐stratification and management
EH Estey - American journal of hematology, 2014 - Wiley Online Library
Overview: Evidence suggest that even patients aged 70 or above benefit from specific AML
therapy. The fundamental decision in AML then becomes whether to recommend standard …
therapy. The fundamental decision in AML then becomes whether to recommend standard …
Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation
Purpose Age has long been used as a major factor for assessing suitability for allogeneic
hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was …
hematopoietic cell transplantation (HCT). The HCT-comorbidity index (HCT-CI) was …
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
In this study, we evaluated trends and outcomes of allogeneic hematopoietic cell
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …
transplantation (HCT) in adults≥ 70 years with hematologic malignancies across the United …
Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: a prospective randomized …
Purpose To compare a reduced-intensity conditioning regimen (RIC) with a myeloablative
conditioning regimen (MAC) before allogeneic transplantation in patients with …
conditioning regimen (MAC) before allogeneic transplantation in patients with …
[HTML][HTML] Survival for older patients with acute myeloid leukemia: a population-based study
B Oran, DJ Weisdorf - Haematologica, 2012 - ncbi.nlm.nih.gov
Background Acute myeloid leukemia is the second most common leukemia among United
States adults with a median age of 69 years. We investigated recent clinical practices related …
States adults with a median age of 69 years. We investigated recent clinical practices related …